Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 688 results
Found 688 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

T

M Villarino E, Scott NA, Weis SE, et al. "Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid." JAMA Pediatr. 2015;169(3):247-55.
Kassaye SG, Grossman Z, Balamane M, et al. "Transmitted HIV Drug Resistance Is High and Longstanding in Metropolitan Washington, DC." Clin. Infect. Dis.. 2016.
Almeida C-AM, Bronke C, Roberts SG, et al. "Translation of HLA-HIV associations to the cellular level: HIV adapts to inflate CD8 T cell responses against Nef and HLA-adapted variant epitopes." J. Immunol.. 2011;187(5):2502-13.
Ouyang Z, Buzon MJ, Zheng L, et al. "Transcriptional Changes in CD8(+) T Cells During Antiretroviral Therapy Intensified With Raltegravir." Open Forum Infect Dis. 2015;2(2):ofv045.
Mukherjee PK, Chen H, Patton LL, et al. "Topical gentian violet compared with nystatin oral suspension for the treatment of oropharyngeal candidiasis in HIV-1-infected participants." AIDS. 2017;31(1):81-88.
Funderburg N, Luciano AA, Jiang W, Rodriguez B, Sieg SF, Lederman MM. "Toll-like receptor ligands induce human T cell activation and death, a model for HIV pathogenesis." PLoS ONE. 2008;3(4):e1915.
Yonkers NL, Rodriguez B, Milkovich KA, et al. "TLR ligand-dependent activation of naive CD4 T cells by plasmacytoid dendritic cells is impaired in hepatitis C virus infection." J. Immunol.. 2007;178(7):4436-44.
Havlir DV, Kendall MA, Ive P, et al. "Timing of antiretroviral therapy for HIV-1 infection and tuberculosis." N. Engl. J. Med.. 2011;365(16):1482-91.
Wilkin TJ, Su Z, Krambrink A, et al. "Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients." J. Acquir. Immune Defic. Syndr.. 2010;54(5):470-6.
Gulick RM, Ribaudo HJ, Shikuma CM, et al. "Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial." JAMA. 2006;296(7):769-81.
Sterling TR, Scott NA, Miro JM, et al. "Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons." AIDS. 2016;30(10):1607-15.
Sterling TR, M Villarino E, Borisov AS, et al. "Three months of rifapentine and isoniazid for latent tuberculosis infection." N. Engl. J. Med.. 2011;365(23):2155-66.
Andrade A, Rosenkranz SL, Cillo AR, et al. "Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248." J. Infect. Dis.. 2013;208(6):884-91.
Mulligan K, Zackin R, Von Roenn JH, et al. "Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trial." J. Clin. Endocrinol. Metab.. 2007;92(2):563-70.
Wood BR, Komarow L, Zolopa AR, Finkelman MA, Powderly WG, Sax PE. "Test performance of blood beta-glucan for Pneumocystis jirovecii pneumonia in patients with AIDS and respiratory symptoms." AIDS. 2013;27(6):967-72.
Johnson DC, Chasela C, Maliwichi M, et al. "Tenofovir use and renal insufficiency among pregnant and general adult population of HIV-infected, ART-naïve individuals in Lilongwe, Malawi." PLoS ONE. 2012;7(7):e41011.
Reynolds NR, Testa MA, Su M, et al. "Telephone support to improve antiretroviral medication adherence: a multisite, randomized controlled trial." J. Acquir. Immune Defic. Syndr.. 2008;47(1):62-8.
Thomas AS, Jones KL, Gandhi RT, et al. "T-cell responses targeting HIV Nef uniquely correlate with infected cell frequencies after long-term antiretroviral therapy." PLoS Pathog.. 2017;13(9):e1006629.
Hulgan T, Robbins GK, Kalams SA, et al. "T cell activation markers and African mitochondrial DNA haplogroups among non-Hispanic black participants in AIDS clinical trials group study 384." PLoS ONE. 2012;7(8):e43803.

S

Tebas P, Zhang J, Yarasheski K, et al. "Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s)." J. Acquir. Immune Defic. Syndr.. 2007;45(2):193-200.
Sherman KE, Andersen JW, Butt AA, et al. "Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C)." J. Acquir. Immune Defic. Syndr.. 2010;55(5):597-605.
Godfrey C, Tauscher G, Hunsberger S, et al. "A survey of tuberculosis infection control practices at the NIH/NIAID/DAIDS-supported clinical trial sites in low and middle income countries." BMC Infect. Dis.. 2016;16:269.
Yamamoto T, Price DA, Casazza JP, et al. "Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection." Blood. 2011;117(18):4805-15.
Kalayjian RC, Franceschini N, Gupta SK, et al. "Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease." AIDS. 2008;22(4):481-7.
Schouten JT, Krambrink A, Ribaudo HJ, et al. "Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095." Clin. Infect. Dis.. 2010;50(5):787-91.
Pei L, Hughes MD. "A statistical framework for quantile equivalence clinical trials with application to pharmacokinetic studies that bridge from HIV-infected adults to children." Biometrics. 2008;64(4):1117-25.
Liu D, Yu J, Chen H, Reichman R, Wu H, Jin X. "Statistical determination of threshold for cellular division in the CFSE-labeling assay." J. Immunol. Methods. 2006;312(1-2):126-36.
Brown TT, Smurzynski M, Wu K, Bosch RJ, McComsey GA. "Statin therapy and changes in hip circumference among HIV-infected participants in the ALLRT Cohort." Antivir. Ther. (Lond.). 2009;14(6):853-8.
Sieg SF, Bazdar DA, Lederman MM. "S-phase entry leads to cell death in circulating T cells from HIV-infected persons." J. Leukoc. Biol.. 2008;83(6):1382-7.
Tenorio AR, Zheng Y, Bosch RJ, et al. "Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment." J. Infect. Dis.. 2014;210(8):1248-59.

Pages